- Home
- INKT vs KALA Comparison
INKT vs KALA Comparison
Compare INKT & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INKT
- KALA
- Stock Information
- Founded
- INKT 2017
- KALA 2009
- Country
- INKT United States
- KALA United States
- Employees
- INKT N/A
- KALA N/A
- Industry
- INKT Medicinal Chemicals and Botanical Products
- KALA Biotechnology: Pharmaceutical Preparations
- Sector
- INKT Health Care
- KALA Health Care
- Exchange
- INKT Nasdaq
- KALA Nasdaq
- Market Cap
- INKT 28.8M
- KALA 26.2M
- IPO Year
- INKT 2021
- KALA 2017
- Fundamental
- Price
- INKT $25.60
- KALA $6.08
- Analyst Decision
- INKT Hold
- KALA Strong Buy
- Analyst Count
- INKT 3
- KALA 3
- Target Price
- INKT $37.50
- KALA $14.00
- AVG Volume (30 Days)
- INKT 2.7M
- KALA 133.6K
- Earning Date
- INKT 08-12-2025
- KALA 08-05-2025
- Dividend Yield
- INKT N/A
- KALA N/A
- EPS Growth
- INKT N/A
- KALA N/A
- EPS
- INKT N/A
- KALA N/A
- Revenue
- INKT N/A
- KALA N/A
- Revenue This Year
- INKT N/A
- KALA N/A
- Revenue Next Year
- INKT N/A
- KALA N/A
- P/E Ratio
- INKT N/A
- KALA N/A
- Revenue Growth
- INKT N/A
- KALA N/A
- 52 Week Low
- INKT $4.56
- KALA $2.92
- 52 Week High
- INKT $76.00
- KALA $11.20
- Technical
- Relative Strength Index (RSI)
- INKT 58.01
- KALA 58.29
- Support Level
- INKT $6.80
- KALA $5.39
- Resistance Level
- INKT $76.00
- KALA $7.00
- Average True Range (ATR)
- INKT 6.24
- KALA 0.71
- MACD
- INKT 2.84
- KALA 0.04
- Stochastic Oscillator
- INKT 29.68
- KALA 51.89
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.